Best Coagulation Disorders Doctors in Highlands Ranch, CO

Dr. Kahn is board certified in Obstetrics and Gynecology and Maternal-Fetal Medicine. She graduated from Wellesley College with a major in music and graduated medical school at Columbia College of Physicians and Surgeons in New York City. She completed her internship, residency and maternal-fetal medicine fellowship at the University of Colorado. Dr. Kahn joined Obstetrix Medical Group of Colorado in 2009 and rejoined Obstetrix in 2014 after a year practicing maternal-fetal medicine in New Zealand.

Dr. Stettler was born and raised in Texas. He received his bachelor's degree from the University of Texas and medical degree from the University of Texas Medical Branch in Galveston. He completed his OB-GYN internship and residency at John Peter Smith Hospital in Fort Worth and his Maternal-Fetal Medicine fellowship training at The University of Texas-Southwestern Medical Center in Dallas. Dr. Stettler is board certified in OB/GYN and Maternal-Fetal Medicine. Dr. Stettler served as the Medical Director of the Obstetrix practice in Ft. Worth until 2001 and is now the Medical Director for Obstetrix Medical Group of Colorado.

Amy Adelberg, MD, is a native of Louisville, KY. She graduated from Georgetown University and went home for medical school to the University of Louisville. After completing residency in Obstetrics and Gynecology at Good Samaritan Hospital in CIncinnati, OH, she moved to Chapel Hill, NC for fellowship training in Maternal-Fetal Medicine at the University of North Carolina. She has been a part of the Obstetrix practice since completion of her fellowship in 2004 and enjoys time with her family in the outdoors of Colorado.

I stress continuity of care and access to state-of-the-art therapies and treatments. It's essential to rapidly develop therapies and provide them to patients.

I believe in providing premier oncology care that is individualized to the patients needs and personal beliefs. This encompasses both standard therapies and cutting-edge drugs and therapies that are at the forefront of oncology research and are not available elsewhere in our community.